MP-103

**MP-103** is a non-racemic enantiomeric mixture (3:1 ratio of R to S enantiomers) of fluorobenzenesulfonyl derivatives of 1,4-diazabicyclo[4.3.0]nonan-9-one, developed as an oral glutamate signaling modulator for neuropathic pain. It exhibits superior anti-hyperalgesic and anti-allodynic efficacy compared to the racemic mixture or individual enantiomers in rodent models of paclitaxel-, oxaliplatin-, vincristine-, and MIA-induced neuropathic pain, with effects observed in von Frey and hot plate tests. The compound likely modulates ionotropic glutamate receptors, including NMDA receptors, reducing excitatory neurotransmission and glutamate release, similar to related analogs like dimiracetam and MP-101.[1][7][10][13]